 |
Journal articles
(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.
Abstract : Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major "milestones" of this development, from the first syntheses to the recent first injection in man, are described.
Cited literature [45 references]
https://hal.archives-ouvertes.fr/hal-00866975
Contributor : Morgane Le Corre <>
Submitted on : Friday, September 27, 2013 - 3:03:53 PM
Last modification on : Thursday, February 11, 2021 - 9:12:19 AM
Long-term archiving on: : Saturday, December 28, 2013 - 4:30:41 AM
Contributor : Morgane Le Corre <>
Submitted on : Friday, September 27, 2013 - 3:03:53 PM
Last modification on : Thursday, February 11, 2021 - 9:12:19 AM
Long-term archiving on: : Saturday, December 28, 2013 - 4:30:41 AM
File
278306m.pdf
Publisher files allowed on an open archive